FinlandFinland

Major Parkinson's Study Launched

13.11.2004

Espoo - “Dyskinesias often become a serious problem for people with Parkinson's disease. Delaying the onset of these motor complications would therefore offer a real improvement in the quality of life for patients and their families,” said Mary Baker, President of the European Parkinson's Disease Association (EPDA), UK. She welcomed the major study STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation) in Parkinson's disease (PD), which was recently launched by Orion Pharma, a joint business division of Orion Corporation and Novartis.
This study seeks to investigate whether - when used as initial therapy - the optimized Levodopa medication Stalevo, which contains Levodopa, Carbidopa and Entacapone, delays the onset of motor complications, such as dyskinesias, compared with the traditional formulation of Levodopa/Carbidopa. STRIDE-PD will enroll some 740 patients at 70 centres in 14 countries: Austria, Belgium, Canada, France, Finland, Germany, Greece, Italy, Spain, Sweden, Turkey, Switzerland, the United Kingdom and the USA. The first study results are expected in 2007. “If the study shows that Stalevo is superior to the traditional therapy up to the time of onset of dyskinesias, this could change the current treatment paradigm completely,” said Werner Poewe, Chair of the Depart-ment of Neurology at Innsbruck University, Austria. “We would then use Stalevo from the first day in patients needing Levodopa treatment.”
Levodopa is the most effective and most widely used symptomatic PD treatment for nearly 40 years. However, after several years of treatment with Levodopa, patients often begin to experience motor complications, such as “wearing-off” (when the effect of one dose of medication does not last until the next scheduled dose) and dyskinesias.

FinlandFinland

11.02.2011

Helsinki – Using laser light to destroy tumour cells lodged in lymphatic vessels can halt the spread of cancer, Finnish researchers headed by Tuomas Tammela have demonstrated. Their approach to destroy the tumour cells, which use...

FinlandFinland

03.11.2010

Turku/Freiburg – EU researchers led by scientists at the University of Turku have begun designing a bacterium able to produce liquefied petroleum gas (LPG) from sunlight. “We have all the parts to put the ability for production...

FinlandFinland

19.09.2010

Rajamäki/Darmstadt – A cooperation project between AB Enzymes Oy and Royal Oy has resulted in the discovery of an enzyme that enables washing temperature to be dropped to as low as 10° C. The project is being funded by the SymBio...

FinlandFinland

08.07.2010

Turku – Finland’s Faron Pharmaceuticals Ltd. has announced a cooperation with German biotech company Priaxon AG to create new scaffold structures to modify the AOC3-protein function and its ligand interaction with orally...

FinlandFinland

09.06.2010

Tampere – Short people are at greater risk of developing heart disease than tall people, according to a meta-analysis of 52 populations-based studies including 3 million people by Finnish researchers (Eur. Heart J.,...

FinlandFinland

12.05.2010

Reykjavik – Researchers from the Icelandic bio­tech company deCODE – together with colleagues from 23 institutions in a dozen countries – have determined that genetic factors influence both nico­tine dependence and the incidence...

FinlandFinland

11.05.2010

Turku – Finnish Biotie Therapies Corp. confirmed that its oral phospho­diesterase 4 inhibitor ELB353 has proven safe and pharmacologically active in a Phase I study. Pharmacokinetic data point to the suitability of ELB353 for a...

FinlandFinland

07.03.2010

Helsinki/Hinxton – Finland has pledged EUR1.85m to help create world-class bio­informatics, biobanking and translational research infrastructures, the European Bioinformatics Institute (EBI) at the European Molecular Laboratory...

FinlandFinland

04.02.2010

Helsinki –Finland is investing EUR1.9m in creating world class bioinformatics, biobanking and translational research infrastructures. The investment comes as part of the linkage of three large EU projects ELIXIR, BBMRI, and...

Displaying results 11 to 20 out of 96

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/browse/1/article/major-parkinsons-study-launched.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%
  • ADDEX3.98 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%

TOP

  • SANTHERA98.35 CHF64.2%
  • EPIGENOMICS3.37 EUR6.0%
  • BB BIOTECH141.00 EUR5.9%

FLOP

  • WILEX2.25 EUR-20.2%
  • MOLOGEN7.38 EUR-16.3%
  • THERAMETRICS0.08 CHF-11.1%

TOP

  • SANTHERA98.35 CHF4310.3%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.55 EUR-67.3%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 29.08.2014


Current issue

All issues

Product of the week

Products